Hyperlipidemia refers to the condition of elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia).
HYPERLIPIDEMIA THERAPEUTICS UNDER DEVELOPMENT (2018)
Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. Risk factors for hyperlipidemia include obesity, physical inactivity and improper diet with saturated fat content. Disease conditions such as hypothyroidism, diabetes mellitus, liver disease, kidney disease, certain medications, as well as alcoholism can elevate lipid levels. Also, family history of high cholesterol put a person at high risk for hyperlipidemia.
An increase in number of cases of patients with hyperlipidemia is anticipated in coming years due to unhealthy lifestyle. Several factors that increase the risk of hyperlipidemia include unhygienic diet intake with high amount of trans fat, lack of physical activity, obesity, and smoking. Other factors include stress, high blood pressure, type II diabetes mellitus, and thyroid disorders.
Also, with advancements in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat hyperlipidemia. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow the development of specific targeted therapies with effective drug delivery. Thus, the above factors contribute towards the hyperlipidemia pipeline growth.
As of January 2018, the hyperlipidemia therapeutics pipeline comprises of 53 drug candidates in different stages of development.
Some of the key players involved in the development of hyperlipidemia therapeutics include Novartis AG, Eli Lilly and Company and Merck & Co. Inc.